Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "No discrete host molecular pharmacological target" refers to a classification for therapeutic agents that do not achieve their effect by binding to a specific host protein, such as a receptor, enzyme, or transporter (ChEMBL, 2024). Instead, these drugs operate through physicochemical processes, such as the chemical neutralization of gastric acid by antacids or the creation of osmotic gradients by agents like mannitol (Goodman & Gilman, 2023). This category also includes surfactants like simethicone and adsorbents like activated charcoal, which act through physical properties rather than molecular signaling (StatPearls, 2023). Because these agents lack a defined protein binding site, they do not follow standard pharmacological models of potency and affinity (IUPHAR/BGP, 2024). This designation is crucial for maintaining the integrity of drug-target databases by identifying compounds with non-specific mechanisms of action.
Physicochemical interaction (e.g., neutralization, osmosis, adsorption)
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on No discrete host molecular pharmacological target.